What's Happening?
Sanofi has introduced its Dual Targeting Library 2.0 (DTL 2.0), a novel approach in drug discovery aimed at creating bispecific therapeutics. This method involves combining single-targeting molecules in an unbiased manner to discover new bispecific combinations
that can advance into development. The process includes single-target identification, monospecific assembly, unbiased physical pairing, and multi-readout testing to finalize lead bispecific hits. The approach is not a shortcut but rather a means to access novel therapeutic possibilities by exploring unpredictable biological mechanisms.
Why It's Important?
The development of bispecific therapeutics represents a significant advancement in drug discovery, as these molecules can simultaneously target two biological pathways or cell types, potentially leading to more effective treatments. Sanofi's approach could lead to breakthroughs in treating complex diseases that involve multiple biological processes. This innovation could have a profound impact on the pharmaceutical industry by expanding the range of treatable conditions and improving patient outcomes. The use of AI in this process further enhances the potential for discovering novel therapeutic targets.
